Defunct Company
Total Trials
12
As Lead Sponsor
9
As Collaborator
3
Total Enrollment
1,821
NCT01476995
Prognostic Indicators as Provided by the EPIC ClearView
Phase: N/A
Role: Lead Sponsor
Start: Sep 30, 2010
Completion: Jun 30, 2011
NCT01573559
ClearView Predicate Comparison Testing
Start: Sep 30, 2011
Completion: Sep 30, 2011
NCT01476982
Evaluation of Patients in Chest Pain in the Emergency Room
Start: May 31, 2012
Completion: Not specified
NCT01740739
Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors
Start: Nov 30, 2012
Completion: Jun 30, 2013
NCT02287766
Metabolic Syndrome Feasibility Study
Start: Nov 30, 2014
Completion: Aug 31, 2015
NCT02471625
Traumatic Brain Injury Feasibility Study (EPIC-011)
Start: Apr 30, 2015
NCT02880865
Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine
Phase: Phase 4
Role: Collaborator
Start: Oct 13, 2016
Completion: Jul 11, 2017
NCT05088421
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers
Phase: Phase 1
Start: Nov 5, 2021
Completion: May 28, 2023
NCT05942820
The Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of BWC0977 in Healthy Adult Volunteers
Start: Aug 30, 2023
Completion: Feb 15, 2024
NCT06799013
Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever
Start: Jul 10, 2025
Completion: Jul 31, 2027
NCT07181486
Safety Study of MucoCept-CVN
Start: Sep 22, 2025
Completion: Oct 31, 2027
NCT07029932
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Ascending Doses of BWC0977 in Healthy Volunteers
Start: Oct 10, 2025
Completion: Aug 30, 2026